-
1.
公开(公告)号:WO2008107478A8
公开(公告)日:2008-10-23
申请号:PCT/EP2008052764
申请日:2008-03-07
Applicant: JANSSEN PHARMACEUTICA NV , VIALARD JORGE EDUARDO , ANGIBAUD PATRICK RENE , MEVELLEC LAURENCE ANNE , MEYER CHRISTOPHE , FREYNE EDDY JEAN EDGARD , PILATTE ISABELLE NOELLE CONSTANCE , ROUX BRUNO , PASQUIER ELISABETH THERESE JEANNE , BOURDREZ XAVIER MARC , ADELINET CHRISTOPHE DENIS , MARCONNET-DECRANE LAURENCE FRANCOISE BERNADETTE , MACRITCHIE JACQUELINE ANNE , DUFFY JAMES EDWARD STEWART , OWENS ANDREW PATE , STORCK PIERRE-HENRI , PONCELET VIRGINIE SOPHIE
Inventor: VIALARD JORGE EDUARDO , ANGIBAUD PATRICK RENE , MEVELLEC LAURENCE ANNE , MEYER CHRISTOPHE , FREYNE EDDY JEAN EDGARD , PILATTE ISABELLE NOELLE CONSTANCE , ROUX BRUNO , PASQUIER ELISABETH THERESE JEANNE , BOURDREZ XAVIER MARC , ADELINET CHRISTOPHE DENIS , MARCONNET-DECRANE LAURENCE FRACOISE BERNADETTE , MACRITCHIE JACQUELINE ANNE , DUFFY JAMES EDWARD STEWART , OWENS ANDREW PATE , STORCK PIERRE-HENRI , PONCELET VIRGINIE SOPHIE
IPC: C07D215/22 , A61K31/4704
CPC classification number: C07D215/227 , C07D401/06 , C07D401/12 , C07D405/06 , C07D409/06 , C07D413/06 , C07D417/06
Abstract: The present invention provides compounds of Formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n, m and X have defined meanings.
Abstract translation: 本发明提供式(I)化合物,其作为PARP抑制剂的用途以及包含所述化合物的药物组合物,其中R 1,R 2,R 2, R 4,R 4,R 5,R 6,R 7,n,m和 X已经定义了含义。
-
公开(公告)号:CA2678248C
公开(公告)日:2016-06-28
申请号:CA2678248
申请日:2008-03-07
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: VIALARD JORGE EDUARDO , ANGIBAUD PATRICK RENE , MEVELLEC LAURENCE ANNE , MEYER CHRISTOPHE , FREYNE EDDY JEAN EDGARD , PILATTE ISABELLE NOELLE CONSTANCE , ROUX BRUNO , PASQUIER ELISABETH THERESE JEANNE , BOURDREZ XAVIER MARC , ADELINET CHRISTOPHE DENIS , MARCONNET-DECRANE LAURENCE FRANCOISE BERNADETTE , MACRITCHIE JACQUELINE ANNE , DUFFY JAMES EDWARD STEWART , OWENS ANDREW PATE , STORCK PIERRE-HENRI , PONCELET VIRGINIE SOPHIE
IPC: C07D215/22 , A61K31/4704
Abstract: The present invention provides compounds of Formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds, wherein R1, R2, R3, R4, R5, R6, R7, n, m and X have defined meanings.
-
公开(公告)号:AU2008223793A1
公开(公告)日:2008-09-12
申请号:AU2008223793
申请日:2008-03-07
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: PASQUIER ELISABETH THERESE JEANNE , DUFFY JAMES EDWARD STEWART , BOURDREZ XAVIER MARC , OWENS ANDREW PATE , FREYNE EDDY JEAN EDGARD , PONCELET VIRGINIE SOPHIE , ROUX BRUNO , MACRITCHIE JACQUELINE ANNE , ANGIBAUD PATRICK RENE , MARCONNET-DECRANE LAURENCE FRANCOISE BERNADETTE , STORCK PIERRE-HENRI , MEYER CHRISTOPHE , MEVELLEC LAURENCE ANNE , VIALARD JORGE EDUARDO , ADELINET CHRISTOPHE DENIS , PILATTE ISABELLE NOELLE CONSTANCE
IPC: C07D215/22 , A61K31/4704
-
公开(公告)号:AT542799T
公开(公告)日:2012-02-15
申请号:AT08717511
申请日:2008-03-07
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: VIALARD JORGE EDUARDO , ANGIBAUD PATRICK RENE , MEVELLEC LAURENCE ANNE , MEYER CHRISTOPHE , FREYNE EDDY JEAN EDGARD , PILATTE ISABELLE NOELLE CONSTANCE , ROUX BRUNO , PASQUIER ELISABETH THERESE JEANNE , BOURDREZ XAVIER MARC , ADELINET CHRISTOPHE DENIS , MARCONNET-DECRANE LAURENCE FRANCOISE , MACRITCHIE JACQUELINE ANNE , DUFFY JAMES EDWARD STEWART , OWENS ANDREW PATE , STORCK PIERRE-HENRI , PONCELET VIRGINIE SOPHIE
IPC: C07D215/22 , A61K31/4704
-
公开(公告)号:PT1037880E
公开(公告)日:2004-11-30
申请号:PT98965820
申请日:1998-12-08
Applicant: JANSSEN PHARMACEUTICA NV
IPC: A61K31/4164 , A61K31/4196 , A61K31/427 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/496 , A61P17/00 , A61P43/00 , C07D207/335 , C07D207/337 , C07D213/40 , C07D233/56 , C07D233/61 , C07D249/08 , C07D257/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D521/00
Abstract: The present invention is concerned with compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents O, S or NR3; R1 represents hydrogen, hydroxy, C1-6alkyl or aryl; R2 represents hydrogen; optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl; aryl; Het1; R3 represents hydrogen, optionally substituted C1-6alkyl, aryl, Het1; R4 represents hydrogen; hydroxy; mercapto; C1-6alkyloxy; C1-6alkylthio; aryloxy; arylthio; Het1-oxy; Het1-thio; optionally substituted C1-12alkyl; optionally substituted C2-8alkenyl; optionally substituted C2-8alkynyl; optionally substituted C3-7cycloalkyl; optionally substituted C5-7cycloalkenyl; aryl; Het1; or -Alk-NR3R5 (i) or -NR3R5 (ii) wherein Alk represents C1-6alkanediyl; and R5 represents hydrogen, C1-6alkyl, aryl, Het1, (aryl or Het1)C1-6alkyl, (aryl or Het1)carbonyl or (aryl or Het1)C1-6alkyloxycarbonyl; aryl represents optionally substituted indanyl, indenyl, naphtyl, 5,6,7,8-tetrahydro-2-naphtalenyl or phenyl; Het is triazolyl; and Het1 represents an optionally substituted monocyclic or bicyclic heterocycle; having retinoic mimetic activity; their preparation, compositions containing them and their use as a medicine.
-
公开(公告)号:SI1037880T1
公开(公告)日:2004-10-31
申请号:SI9830681
申请日:1998-12-08
Applicant: JANSSEN PHARMACEUTICA NV
IPC: A61K31/4164 , A61K31/4196 , A61K31/427 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/496 , A61P17/00 , A61P43/00 , C07D207/335 , C07D207/337 , C07D213/40 , C07D233/56 , C07D233/61 , C07D249/08 , C07D257/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D521/00
Abstract: The present invention is concerned with compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents O, S or NR3; R1 represents hydrogen, hydroxy, C1-6alkyl or aryl; R2 represents hydrogen; optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl; aryl; Het1; R3 represents hydrogen, optionally substituted C1-6alkyl, aryl, Het1; R4 represents hydrogen; hydroxy; mercapto; C1-6alkyloxy; C1-6alkylthio; aryloxy; arylthio; Het1-oxy; Het1-thio; optionally substituted C1-12alkyl; optionally substituted C2-8alkenyl; optionally substituted C2-8alkynyl; optionally substituted C3-7cycloalkyl; optionally substituted C5-7cycloalkenyl; aryl; Het1; or -Alk-NR3R5 (i) or -NR3R5 (ii) wherein Alk represents C1-6alkanediyl; and R5 represents hydrogen, C1-6alkyl, aryl, Het1, (aryl or Het1)C1-6alkyl, (aryl or Het1)carbonyl or (aryl or Het1)C1-6alkyloxycarbonyl; aryl represents optionally substituted indanyl, indenyl, naphtyl, 5,6,7,8-tetrahydro-2-naphtalenyl or phenyl; Het is triazolyl; and Het1 represents an optionally substituted monocyclic or bicyclic heterocycle; having retinoic mimetic activity; their preparation, compositions containing them and their use as a medicine.
-
公开(公告)号:ID21498A
公开(公告)日:1999-06-17
申请号:ID981606
申请日:1998-12-10
Applicant: JANSSEN PHARMACEUTICA NV
IPC: A61K31/4164 , A61K31/4196 , A61K31/427 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/496 , A61P17/00 , A61P43/00 , C07D207/335 , C07D207/337 , C07D213/40 , C07D233/56 , C07D233/61 , C07D249/08 , C07D257/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D521/00 , C07C303/40
Abstract: The present invention is concerned with compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents O, S or NR3; R1 represents hydrogen, hydroxy, C1-6alkyl or aryl; R2 represents hydrogen; optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl; aryl; Het1; R3 represents hydrogen, optionally substituted C1-6alkyl, aryl, Het1; R4 represents hydrogen; hydroxy; mercapto; C1-6alkyloxy; C1-6alkylthio; aryloxy; arylthio; Het1-oxy; Het1-thio; optionally substituted C1-12alkyl; optionally substituted C2-8alkenyl; optionally substituted C2-8alkynyl; optionally substituted C3-7cycloalkyl; optionally substituted C5-7cycloalkenyl; aryl; Het1; or -Alk-NR3R5 (i) or -NR3R5 (ii) wherein Alk represents C1-6alkanediyl; and R5 represents hydrogen, C1-6alkyl, aryl, Het1, (aryl or Het1)C1-6alkyl, (aryl or Het1)carbonyl or (aryl or Het1)C1-6alkyloxycarbonyl; aryl represents optionally substituted indanyl, indenyl, naphtyl, 5,6,7,8-tetrahydro-2-naphtalenyl or phenyl; Het is triazolyl; and Het1 represents an optionally substituted monocyclic or bicyclic heterocycle; having retinoic mimetic activity; their preparation, compositions containing them and their use as a medicine.
-
公开(公告)号:ES2224462T3
公开(公告)日:2005-03-01
申请号:ES98965820
申请日:1998-12-08
Applicant: JANSSEN PHARMACEUTICA NV
IPC: A61K31/4164 , A61K31/4196 , A61K31/427 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/496 , A61P17/00 , A61P43/00 , C07D207/335 , C07D207/337 , C07D213/40 , C07D233/56 , C07D233/61 , C07D249/08 , C07D257/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D521/00
Abstract: Un compuesto que tiene la fórmula **(Fórmula)** un N-óxido, una sal de adición farmacéuticamente aceptable o una forma estereoquímicamente isómera del mismo, en el cual: X representa -O-, S-o NR3-; R1 representa hidrógeno, hidroxi, C1-6alquilo o arilo; R2 representa hidrógeno; C1-12alquilo; C3-7cicloalquilo; C2-8alquenilo; arilo; Het1; o C1-12alquilo sustituido con uno o dos sustituyentes seleccionados de C3-7cicloalquilo, hidroxi, C1-4alquiloxi, ciano, amino, mono- y y di(C1-4alquil)amino, mono- o o ddi(aril-C1, 4alquil)amino, di(aril-C1-4alquil)aminocarboniloxi, (C1-4alquil)(aril-C1-4 alquil)amino, mono- y di(aril)-amino, (C1-4alquil)(di(C1-4alquil)amino-C1-4alquil)-amino, pirrolidinilo, piperidinilo, piperazinilo sustituido opcionalmente con C1, 4alquilo, morfolinilo, perhidro-azepinilo, carboxilo, C C1-4 alquiloxi-carbonilo, aminocarbonilo, mono- y di(C1-4alquil)-aminocarbonilo, arilo, ariloxi y ariltio; o R1 y R2, considerados juntos, pueden formar un radical bivalente de fórmula -R1-R2- en donde -R1-R2- representa-(CH2)n- en donde n es 2, 3, 4, 5 ó 6; R3 representa hidrógeno, C1-6alquilo, arilo, Het1 o C1-6alquilo sustituido con arilo o Het1; R4 representa hidrógeno; hidroxi; mercapto; C1-6alquil-oxi; C C1-6alquiltio; ariloxi; ariltio; Het1-oxi; Het1-tio; C C1-12 alquilosustituido opcionalmente con uno, dos o tres sustituyentes seleccionados cada uno independientemente de halo, hidroxi, mercapto, C1-6alquiloxi, C1-6alquiltio, ariloxi, ariltio, Het1-oxi, , Het1-tio, C3-7cicloalquilo sustituido opcionalmente con hidroxicarbonil-C1-6alquilo, carboxilo, C1-6alquiloxicarbonilo, aril-C1-6alquiloxi, arilC1-6alquiltio, arilo, Het1; C2-8alquenilo sustituido opcionalmente con uno, dos o tres sustituyentes seleccionados de halo, C3-7cicloalquilo, arilo, Het1; C2-8alquinilosustituido opcionalmente con halo, C3-7cicloalquilo, arilo; C3-7cicloalquilo sustituido opcionalmente con C1-6alquilo o arilo; C5-7ciclo-alquenilo sustituido opcionalmente con C1-6alquilo o arilo; arilo; Het1; o-Alk - NR3R5 (i) o -NR3R5 (ii) en donde Alk representa C1-6alcanodiílo; y R5 representa hidrógeno, C1-6alquilo, arilo, Het1, (aril o Het1)C1-6alquilo, (aril o Het1)-carbonilo o o (aril o o Het1) C1-6alquiloxicarbonilo; arilo representa indanilo, indenilo, naftilo, 5, 6, 7, 8-tetrahidro-2-naftalenilo; fenilo; donde dicho indanilo, indenilo, naftilo o fenilo puede estar sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados cada uno independientemente de hidroxi, halo, nitro, ciano, amino, azido, mono- o o di(C1-6alquil)amino, C1-6alquilcarbonilamino, C1-6alquilo, polihalo-C1-6alquilo, hidroxi-C1-6alquilo, fenilo, feniloxi, fenil-C1-6alquiloxi, piridinil-C1-6 alquiloxi, C1-6alquiloxi, formilo, carboxilo, y C1-6alquilcarbonilo; o dos átomos de carbono adyacentes en dicho fenilo pueden estar sustituidos por un solo radical bivalente que tiene la fórmula C1-12alcanodiílo o polihalo C1-12alcanodiílo; Het representa un heterociclo insaturado seleccionado de pirrolilo, pirazolilo, imidazolilo, triazolilo, tetrazolilo y piridinilo; pudiendo estar cada uno de dichos heterociclos insaturados sustituido opcionalmente con amino, mercapto, C1-6alquilo, C1-6alquiltio o arilo; y Het1 representa un heterociclo monocíclico seleccionado de pirrolidinilo, pirrolilo, pirazolilo, imidazolilo, 1, 3, 4-tria -zolilo, 1, 2, 4-triazolilo, tetrahidro-furanilo, furanilo, tiolanilo, tienilo, dioxolanilo, isoxazolilo, oxazolilo, isotiazolilo, tiazolilo, isoxazolidinilo, oxazolidinilo, isotiazolidinilo, tiazolidinilo, piperidinilo, piridinilo, piperazinilo, piridazinilo, pirimidinilo, pirazinilo, 1, 2, 3-triazinilo, 1, 2, 4-triazinilo, tetrahidropiranilo, piranilo, morfolinilo y dioxanilo; pudiendo estar cada uno de dichos heterociclos monocíclicos sustituido opcionalmente con uno o dos sustituyentes seleccionados cada uno independientemente de C1, 4alquilo, hidroxi, amino, halo, arilo, arilcar.
-
公开(公告)号:AT270277T
公开(公告)日:2004-07-15
申请号:AT98965820
申请日:1998-12-08
Applicant: JANSSEN PHARMACEUTICA NV
IPC: A61K31/4164 , A61K31/4196 , A61K31/427 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/496 , A61P17/00 , A61P43/00 , C07D207/335 , C07D207/337 , C07D213/40 , C07D233/56 , C07D233/61 , C07D249/08 , C07D257/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D521/00
Abstract: The present invention is concerned with compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents O, S or NR3; R1 represents hydrogen, hydroxy, C1-6alkyl or aryl; R2 represents hydrogen; optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl; aryl; Het1; R3 represents hydrogen, optionally substituted C1-6alkyl, aryl, Het1; R4 represents hydrogen; hydroxy; mercapto; C1-6alkyloxy; C1-6alkylthio; aryloxy; arylthio; Het1-oxy; Het1-thio; optionally substituted C1-12alkyl; optionally substituted C2-8alkenyl; optionally substituted C2-8alkynyl; optionally substituted C3-7cycloalkyl; optionally substituted C5-7cycloalkenyl; aryl; Het1; or -Alk-NR3R5 (i) or -NR3R5 (ii) wherein Alk represents C1-6alkanediyl; and R5 represents hydrogen, C1-6alkyl, aryl, Het1, (aryl or Het1)C1-6alkyl, (aryl or Het1)carbonyl or (aryl or Het1)C1-6alkyloxycarbonyl; aryl represents optionally substituted indanyl, indenyl, naphtyl, 5,6,7,8-tetrahydro-2-naphtalenyl or phenyl; Het is triazolyl; and Het1 represents an optionally substituted monocyclic or bicyclic heterocycle; having retinoic mimetic activity; their preparation, compositions containing them and their use as a medicine.
-
公开(公告)号:PL341059A1
公开(公告)日:2001-03-26
申请号:PL34105998
申请日:1998-12-08
Applicant: JANSSEN PHARMACEUTICA NV
IPC: A61K31/4164 , A61K31/4196 , A61K31/427 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/496 , A61P17/00 , A61P43/00 , C07D207/335 , C07D207/337 , C07D213/40 , C07D233/56 , C07D233/61 , C07D249/08 , C07D257/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D521/00
Abstract: The present invention is concerned with compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents O, S or NR3; R1 represents hydrogen, hydroxy, C1-6alkyl or aryl; R2 represents hydrogen; optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl; aryl; Het1; R3 represents hydrogen, optionally substituted C1-6alkyl, aryl, Het1; R4 represents hydrogen; hydroxy; mercapto; C1-6alkyloxy; C1-6alkylthio; aryloxy; arylthio; Het1-oxy; Het1-thio; optionally substituted C1-12alkyl; optionally substituted C2-8alkenyl; optionally substituted C2-8alkynyl; optionally substituted C3-7cycloalkyl; optionally substituted C5-7cycloalkenyl; aryl; Het1; or -Alk-NR3R5 (i) or -NR3R5 (ii) wherein Alk represents C1-6alkanediyl; and R5 represents hydrogen, C1-6alkyl, aryl, Het1, (aryl or Het1)C1-6alkyl, (aryl or Het1)carbonyl or (aryl or Het1)C1-6alkyloxycarbonyl; aryl represents optionally substituted indanyl, indenyl, naphtyl, 5,6,7,8-tetrahydro-2-naphtalenyl or phenyl; Het is triazolyl; and Het1 represents an optionally substituted monocyclic or bicyclic heterocycle; having retinoic mimetic activity; their preparation, compositions containing them and their use as a medicine.
-
-
-
-
-
-
-
-
-